骨髓间充质干细胞治疗激素性股骨头坏死的研究进展

doi:10.11958/20221802

天津医药 ›› 2023, Vol. 51 ›› Issue (5): 553-555.doi: 10.11958/20221802

骨髓间充质干细胞治疗激素性股骨头坏死的研究进展

钱士达(), 于雪峰^△()

南昌大学第四附属医院骨科（邮编330003）

收稿日期:2022-11-15 修回日期:2023-01-17 出版日期:2023-05-15 发布日期:2023-05-05
通讯作者: △E-mail:yxf_1958@sina.com
作者简介:钱士达（1996），男，硕士在读，主要从事骨坏死方面研究。E-mail：1554384089@qq.com
基金资助:
国家自然科学基金项目(82174190)

Research progress on bone marrow mesenchymal stem cells in the treatment of steroid-induced osteonecrosis of femoral head

QIAN Shida(), YU Xuefeng^△()

Department of Orthopedics, Fourth Affiliated Hospital of Nanchang University, Nanchang 330003, China

Received:2022-11-15 Revised:2023-01-17 Published:2023-05-15 Online:2023-05-05
Contact: △E-mail:yxf_1958@sina.com

钱士达, 于雪峰. 骨髓间充质干细胞治疗激素性股骨头坏死的研究进展[J]. 天津医药, 2023, 51(5): 553-555.

QIAN Shida, YU Xuefeng. Research progress on bone marrow mesenchymal stem cells in the treatment of steroid-induced osteonecrosis of femoral head[J]. Tianjin Medical Journal, 2023, 51(5): 553-555.

摘要/Abstract

摘要：

激素性股骨头坏死的病因和发生机制尚未完全阐明，且缺乏有效的治疗方法。随着干细胞治疗技术在各大学科的应用，许多学者开始研究干细胞的性质和功能，并应用于激素性股骨头坏死的治疗中。单纯的干细胞移植效果不佳，但对干细胞进行移植前修饰可以提高其疗效。该文就骨髓间充质干细胞治疗激素性股骨头坏死的研究进展进行综述。

关键词: 股骨头坏死, 间质干细胞, 干细胞移植, 激素性股骨头坏死, 骨髓间充质干细胞

Abstract:

The etiology and mechanism of steroid-induced osteonecrosis of femoral head (SONFH) have not been fully elucidated, and effective treatments have not yet emerged. With the application of stem cell therapy technology in various disciplines, the nature and function of stem cells have been extensively studied and applied in the treatment of SONFH. However, stem cell transplantation alone is not effective, and its efficacy can be enhanced by pretransplantation modification. This paper reviews the research progress of bone marrow mesenchymal stem cells in the treatment of SONFH.

Key words: femur head necrosis, mesenchymal stem cells, stem cell transplantation, steroid-induced osteonecrosis of the femoral head, bone marrow mesenchymal stem cell

中图分类号:

R681.802

参考文献 37

[1]	LIN L, YU Y, LIU K, et al. Downregulation of miR-30b-5p facilitates chondrocyte hypertrophy and apoptosis via targeting Runx2 in steroid-induced osteonecrosis of the femoral head[J]. Int J Mol Sci, 2022, 23(19):11275. doi:10.3390/ijms231911275.
[2]	AN F, ZHANG L, GAO H, et al. Variants in RETN gene are associated with steroid-induced osteonecrosis of the femoral head risk among Han Chinese people[J]. J Orthop Surg Res, 2020, 15(1):96. doi:10.1186/s13018-020-1557-3.
[3]	RIEDL M, WITZMANN C, KOCH M, et al. Attenuation of hypertrophy in human MSCs via treatment with a retinoic acid receptor inverse agonist[J]. Int J Mol Sci, 2020, 21(4):1444. doi:10.3390/ijms21041444.
[4]	TAN B, LI W, ZENG P, et al. Epidemiological study based on china osteonecrosis of the femoral head database[J]. Orthop Surg, 2021, 13(1):153-160. doi:10.1111/os.12857.
[5]	XU Y, JIANG Y, WANG Y, et al. LINC00473-modified bone marrow mesenchymal stem cells incorporated thermosensitive PLGA hydrogel transplantation for steroid-induced osteonecrosis of femoral head:A detailed mechanistic study and validity evaluation[J]. Bioeng Transl Med, 2022, 7(2):e10275. doi:10.1002/btm2.10275.
[6]	WANG L, TIAN X, LI K, et al. Combination use of core decompression for osteonecrosis of the femoral head:A systematic review and Meta-analysis using Forest and Funnel Plots[J]. Comput Math Methods Med, 2021, 2021:1284149. doi:10.1155/2021/1284149.
[7]	LU G D, CHENG P, LIU T, et al. BMSC-derived exosomal miR-29a promotes angiogenesis and osteogenesis[J]. Front Cell Dev Biol, 2020, 8:608521. doi:10.3389/fcell.2020.608521.
[8]	CHEN Q, SHOU P, ZHENG C, et al. Fate decision of mesenchymal stem cells:adipocytes or osteoblasts?[J]. Cell Death Differ, 2016, 23(7):1128-1139. doi:10.1038/cdd.2015.168.
[9]	JIANG Y, JAHAGIRDAR B N, REINHARDT R L, et al. Pluripotency of mesenchymal stem cells derived from adult marrow[J]. Nature, 2002, 418(6893):41-49. doi:10.1038/nature00870.
[10]	WANG Z, LI X, YANG J, et al. Single-cell RNA sequencing deconvolutes the in vivo heterogeneity of human bone marrow-derived mesenchymal stem cells[J]. Int J Biol Sci, 2021, 17(15):4192-4206. doi:10.7150/ijbs.61950.
[11]	SUN Y, YUAN Y, WU W, et al. The effects of locomotion on bone marrow mesenchymal stem cell fate:insight into mechanical regulation and bone formation[J]. Cell Biosci, 2021, 11(1):88. doi:10.1186/s13578-021-00601-9.
[12]	YU D, ZHANG S, MA C, et al. CCL3 in the bone marrow microenvironment causes bone loss and bone marrow adiposity in aged mice[J]. JCI Insight, 2023, 8(1):e159107. doi:10.1172/jci.insight.159107.
[13]	FANG S, HE T, JIANG J, et al. Osteogenic effect of tsRNA-10277-loaded exosome derived from bone mesenchymal stem cells on steroid-induced osteonecrosis of the femoral head[J]. Drug Des Devel Ther, 2020, 14:4579-4591. doi:10.2147/DDDT.S258024.
[14]	HE Y, ZOU L. Notch-1 inhibition reduces proliferation and promotes osteogenic differentiation of bone marrow mesenchymal stem cells[J]. Exp Ther Med, 2019, 18(3):1884-1890. doi:10.3892/etm.2019.7765.
[15]	LOWERY J W, ROSEN V. The BMP pathway and its inhibitors in the skeleton[J]. Physiol Rev, 2018, 98(4):2431-2452. doi:10.1152/physrev.00028.2017.
[16]	SOTTILE V, SEUWEN K. Bone morphogenetic protein-2 stimulates adipogenic differentiation of mesenchymal precursor cells in synergy with BRL 49653 (rosiglitazone)[J]. FEBS Lett, 2000, 475(3):201-204. doi:10.1016/s0014-5793(00)01655-0.
[17]	LORIES R J, MONTEAGUDO S. Review article:is Wnt signaling an attractive target for the treatment of osteoarthritis?[J]. Rheumatol Ther, 2020, 7(2):259-270. doi:10.1007/s40744-020-00205-8.
[18]	LAINEZ-GONZALEZ D, SERRANO-LOPEZ J, ALONSO-DOMINGUEZ J M. Understanding the Notch signaling pathway in acute myeloid leukemia stem cells:from hematopoiesis to neoplasia[J]. Cancers (Basel), 2022, 14(6):1459. doi:10.3390/cancers14061459.
[19]	KONG L, ZUO R, WANG M, et al. Silencing microRNA-137-3p,which targets RUNX2 and CXCL12 prevents steroid-induced osteonecrosis of the femoral head by facilitating osteogenesis and angiogenesis[J]. Int J Biol Sci, 2020, 16(4):655-670. doi:10.7150/ijbs.38713.
[20]	BRUDER S P, JAISWAL N, HAYNESWORTH S E. Growth kinetics,self-renewal,and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation[J]. J Cell Biochem, 1997, 64(2):278-294.
[21]	孙伟, 高福强, 李子荣. 股骨头坏死临床诊疗技术专家共识(2022年)[J]. 中国修复重建外科杂志, 2022, 36(11):1319-1326.
	SUN W, GAO F Q, LI Z R. Expert consensus on clinical diagnosis and treatment technique of osteonecrosis of the femoral head (2022 version)[J]. Chinese Journal of Reparative and Reconstructive Surgery, 2022, 36(11):1319-1326. doi:10.7507/1002-1892.202207134.
[22]	MA J, WANG B, YUE D, et al. Outcomes of conversion THA after failed porous tantalum implant for osteonecrosis of the femoral head:A comparative matched study[J]. Hip Int, 2020, 30(6):703-710. doi:10.1177/1120700019863036.
[23]	KURODA Y, OKUZU Y, KAWAI T, et al. Difference in therapeutic strategies for joint-preserving surgery for non-traumatic osteonecrosis of the femoral head between the United States and Japan:A review of the literature[J]. Orthop Surg, 2021, 13(3):742-748. doi:10.1111/os.12979.
[24]	LEE Y K, LEE B, PARVIZI J, et al. Which osteotomy for osteonecrosis of the femoral head and which patient for the osteotomy?[J]. Clin Orthop Surg, 2019, 11(2):137-141. doi:10.4055/cios.2019.11.2.137.
[25]	KANG J S, SUH Y J, MOON K H, et al. Clinical efficiency of bone marrow mesenchymal stem cell implantation for osteonecrosis of the femoral head:A matched pair control study with simple core decompression[J]. Stem Cell Res Ther, 2018, 9(1):274. doi:10.1186/s13287-018-1030-y.
[26]	WANG S L, HU Y B, CHEN H, et al. Efficacy of bone marrow stem cells combined with core decompression in the treatment of osteonecrosis of the femoral head:A PRISMA-compliant meta-analysis[J]. Medicine (Baltimore), 2020, 99(25):e20509. doi:10.1097/MD.0000000000020509.
[27]	ZHU S, ZHANG X, CHEN X, et al. Comparison of cell therapy and other novel adjunctive therapies combined with core decompression for the treatment of osteonecrosis of the femoral head:A systematic review and Meta-analysis of 20 studies[J]. Bone Joint Res, 2021, 10(7):445-458. doi: 10.1302/2046-3758.107.BJR-2020-0418.R1.
[28]	LIGHTNER A L, REAM J, NACHAND D, et al. Remestemcel-L allogeneic bone marrow-derived mesenchymal stem cell product to treat medically refractory Crohn's colitis:preliminary phase IB/IIA study[J]. Br J Surg, 2022, 109(8):653-655. doi:10.1093/bjs/znac078.
[29]	ZHANG L, XI Y, GUO R, et al. Bone marrow mesenchymal stem cell-mediated radiosensitive promoter-combined sodium iodide symporter for the treatment of breast cancer[J]. Hum Gene Ther, 2022, 33(11/12):638-648. doi:10.1089/hum.2021.144.
[30]	WU Z Y, SUN Q, LIU M, et al. Correlation between the efficacy of stem cell therapy for osteonecrosis of the femoral head and cell viability[J]. BMC Musculoskelet Disord, 2020, 21(1):55. doi:10.1186/s12891-020-3064-4.
[31]	ZHANG F, PENG W, WANG T, et al. Lnc Tmem235 promotes repair of early steroid-induced osteonecrosis of the femoral head by inhibiting hypoxia-induced apoptosis of BMSCs[J]. Exp Mol Med, 2022, 54(11):1991-2006. doi:10.1038/s12276-022-00875-0.
[32]	SHIU S T, LEE W F, CHEN S M, et al. Effect of different bone grafting materials and mesenchymal stem cells on bone regeneration:A micro-computed tomography and histomorphometric study in a rabbit calvarial defect model[J]. Int J Mol Sci, 2021, 22(15):8101. doi:10.3390/ijms22158101.
[33]	HERNANDEZ A, NUNEZ J H, SALLENT A, et al. Core decompression combined with implantation of autologous bone marrow concentrate with tricalcium phosphate does not prevent radiographic progression in early stage osteonecrosis of the hip[J]. Clin Orthop Surg, 2020, 12(2):151-157. doi:10.4055/cios19033.
[34]	HOUDEK M T, WYLES C C, SMITH J H, et al. Hip decompression combined with bone marrow concentrate and platelet-rich plasma for corticosteroid-induced osteonecrosis of the femoral head :mid-term update from a prospective study[J]. Bone Jt Open, 2021, 2(11):926-931. doi:10.1302/2633-1462.211.BJO-2021-0132.R1.
[35]	ZHANG F, PENG W, ZHANG J, et al. P53 and Parkin co-regulate mitophagy in bone marrow mesenchymal stem cells to promote the repair of early steroid-induced osteonecrosis of the femoral head[J]. Cell Death Dis, 2020, 11(1):42. doi:10.1038/s41419-020-2238-1.
[36]	YANG F, XUE F, GUAN J, et al. Stromal-cell-derived factor (SDF) 1-alpha overexpression promotes bone regeneration by osteogenesis and angiogenesis in osteonecrosis of the femoral head[J]. Cell Physiol Biochem, 2018, 46(6):2561-2575. doi:10.1159/000489684.
[37]	ZHANG Y L, ZHU Z Z, ZHANG L C, et al. Lithium chloride prevents glucocorticoid-induced osteonecrosis of femoral heads and strengthens mesenchymal stem cell activity in rats[J]. Chin Med J (Engl), 2021, 134(18):2214-2222. doi:10.1097/CM9.0000000000001530.

骨髓间充质干细胞治疗激素性股骨头坏死的研究进展

Research progress on bone marrow mesenchymal stem cells in the treatment of steroid-induced osteonecrosis of femoral head

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

参考文献 37

相关文章 15

编辑推荐

Metrics

本文评价

[1]	周丽芸, 王岩, 董本超, 杨培川, 申佳慧, 马剑雄, 马信龙. 干细胞机械敏感性对抗骨质疏松症研究进展[J]. 天津医药, 2024, 52(8): 877-881.
[2]	刘丹阳, 李永涛, 张海燕, 李林, 刘洋, 沈雷. 乳腺癌细胞条件培养基对骨髓间充质干细胞生物学行为的影响[J]. 天津医药, 2024, 52(5): 454-458.
[3]	王扶凝, 代会博, 单云, 俞曼殊, 盛梅笑. 骨髓间充质干细胞对腹膜间皮细胞凋亡的影响[J]. 天津医药, 2024, 52(2): 113-118.
[4]	钟家帅, 冯玉梅. 小鼠骨髓和脂肪间充质干细胞定向分化能力的比较研究[J]. 天津医药, 2024, 52(2): 129-135.
[5]	王鑫瑶, 杨惠, 李冰冰. 间充质干细胞在子宫内膜异位症中的研究进展[J]. 天津医药, 2024, 52(2): 215-219.
[6]	侯永波, 余骏马, 朱海娟. 外泌体在心肌梗死治疗中的研究新进展[J]. 天津医药, 2023, 51(9): 1016-1019.
[7]	王娟, 赵玉霞, 茹雅维, 汪子涵, 付婷, 李光. 二甲双胍对Ⅰ型成骨不全小鼠间充质干细胞成骨分化的影响及疗效探讨[J]. 天津医药, 2023, 51(8): 830-833.
[8]	杨雨涛, 王袁, 谢嘉欣, 付霞霏. 人骨髓间充质干细胞来源外泌体分离、鉴定及卵巢摄取[J]. 天津医药, 2023, 51(5): 468-472.
[9]	赵元元, 吴小华. hUC-MSCs来源的外泌体miR-1260a影响PCOS患者颗粒细胞凋亡的研究[J]. 天津医药, 2023, 51(4): 337-343.
[10]	聂进, 刘代顺, 张建勇, 刘楚, 周亮. 脐带间充质干细胞外泌体对慢性阻塞性肺疾病大鼠肺部炎症的作用机制探讨[J]. 天津医药, 2023, 51(12): 1326-1331.
[11]	杜鹏, 王峰, 陈晓波, 郑燕, 吴倩倩, 刘卫军, 王玉亮. 年龄对人脂肪来源间充质干细胞生物学特性的影响[J]. 天津医药, 2022, 50(9): 912-916.
[12]	邢逸, 窦一鸣, 王敏, 徐海楠, 杨强, 孙逊, 赵艳红 . 骨髓间充质干细胞来源外泌体对炎症微环境中巨噬细胞表型及软骨细胞的调控作用[J]. 天津医药, 2022, 50(4): 343-349.
[13]	纪沣轩, 李国鹏, 毕彤, 张维民, 贾庆运, 韦标方. 非创伤性股骨头坏死患者血清颗粒蛋白前体表达及临床意义[J]. 天津医药, 2022, 50(12): 1302-1305.
[14]	张亦朦, 张宇新, 田发明. 骨质疏松hub基因筛选验证及互作miRNA预测[J]. 天津医药, 2022, 50(11): 1158-1164.
[15]	岳宗进, 刘汝银△, 于露, 王新立, 冯仲锴, 王西彬. 葛根总皂苷调控NAMPT-Sirt1轴诱导BMSCs向髓核样细胞分化#br#[J]. 天津医药, 2021, 49(9): 897-903.